This study aimed to analyze the association between cytokine gene polymorphisms and outcome following allogeneic hematopoietic SCT (allo-HSCT). A total of 138 unrelated donor/recipient pairs who underwent allo-HSCT from 2001 to 2009 were tested for TNFA-1031 (T4C), -863 (C4A), -857 (C4T), -238 (G4A), TNFB þ 252 (A4G) and TNFRII codon 196 (T4G) single nucleotide polymorphisms by multiplex SnaPshot analysis. Transplantation involving recipients and/or donors with TNFA-857 C/C genotype or TNFB þ 252 G allele-positivity resulted in a higher incidence of acute GVHD (aGVHD), which was independent of HLA mismatching. In multivariate analysis, TNFA-857 C/C genotype donors (relative risk (RR) ¼ 2.29, P ¼ 0.006) and TNFB þ 252 G allele-positive recipients (RR ¼ 1.789, P ¼ 0.036) were found to be significantly associated with an increased incidence of aGVHD. TNFA-857 C/C genotype donors (RR ¼ 3.748, P ¼ 0.002) and TNFB þ 252 G allele-positive recipients (RR ¼ 1.823, P ¼ 0.063) were also associated with the development of grades II-IV aGVHD. TNFRII polymorphism in recipients was also related to relapse rate, but no significant associations were found between TNFA, TNFB or TNFRII 196 genotype and cGVHD, relapse or overall survival after transplantation. These results provide the first report of an association between TNFA, TNFB and TNFRII polymorphic features and outcome of allo-HSCT in a Chinese population, and suggest an interaction between TNFA-857 and TNFB þ 252 genotypes and risk of aGVHD.
Introduction
Despite advances in HLA-typing methods and post transplantation immune suppression, GVHD remains a significant cause of transplant-related mortality and morbidity following allogeneic hematopoietic SCT (allo-HSCT). 1 HLA disparity is central to the development of GVHD, but 430% of patients receiving an unrelated HLA-matched transplant still develop severe (grades III-IV) acute GVHD (aGVHD). 2 It is now appreciated that the initiation and propagation of GVHD is a multifactorial, multistep process that includes, but is not restricted to, classic HLA allorecognition. 3 In the last 10 years, non-HLA genotypes, include cytokine gene polymorphisms, have been investigated for their potential roles in the occurrence and severity of GVHD, as well as for their contribution to overall transplant-related mortality, infectious episodes and overall survival. 4, 5 TNF, including TNF-a and TNF-b (also called lymphotoxin a), is a multifunctional proinflammatory cytokine that can activate dendritic cells presenting heterologous antigens, increase HLA class I and class II expression, facilitate T-cell activation and cause apoptosis. Since the 1990s, clinical data and data from animal models have shown that the occurrence and severity of aGVHD are associated with increased serum TNF-a levels during pretransplant conditioning. [6] [7] [8] The importance of TNF in both the initial preconditioning and effector phases of aGVHD is now well established. 9 The genes coding for TNF-a (TNFA) and TNF-b (TNFB, also called LTA) lie in the class III region of the MHC and contain multiple single nucleotide polymorphisms (SNPs) in the promoter and transcription start sites. 10 Some of these polymorphisms have been reported to be associated with differences in TNF-a or TNF-b production. 11 The actions of TNF-a are mediated by two distinct receptors: a 55-60-kDa type I receptor (TNFRI) and a 75-80-kDa type II receptor (TNFRII). An SNP has been found in exon 6 at codon 196 (ATG-AGG) in TNFRII gene. This polymorphism results in a non-conservative amino-acid substitution (methionine (M)-arginine (R)). Some studies have demonstrated an association between this polymorphism and susceptibility to immunological diseases. 12, 13 Data regarding the relationship between TNF gene polymorphisms and outcome of allo-HSCT are inconsistent, and there are no data on this relationship in the Chinese population. This study aimed to investigate the association between TNFA, TNFB and TNFRII gene polymorphisms of both donors and recipients and outcome of unrelated allo-HSCT in the Chinese population.
Materials and methods

Characteristics of the HSCT patient group
In total, 138 consecutive pairs of patients and their respective donors, who received unrelated donor HSCT from January 2001 to March 2009 in our Bone Marrow Transplantation Unit were studied for the incidence of aGVHD, chronic GVHD (cGVHD) and overall survival in relation to TNFA, TNFB and TNFRII gene polymorphisms (Table 1 ). All the patients and their donors were of Chinese origin. The study was approved by the local ethics committee. All the patients and donors gave their written informed consent.
Low-resolution HLA typing had been performed for HLA-A, -B and -DRB1 and high-resolution DNA typing for HLA-A, -B, -C, -DRB1 and -DQB1.
The main myeloablative-conditioning regimens were BuCy or BuCy combined with etoposide, cytarabine or semustine without total body irradiation. Reduced-intensity conditioning regimens were predominantly fludarabine-based combinations without irradiation. Routine GVHD prophylaxis consisted of CsA, short-term MTX and mycophenolate mofetil. CsA was scheduled to be given at 2.5 mg/kg/day intravenously from day À1, with a target blood level of 200-300 ng/mL. The dosage was tapered during the second month post transplantation, according to chimeric status and evidence of GVHD. Mycophenolate mofetil was started orally at 500 mg/day on day þ 1, tapered from day þ 28 and withdrawn on day þ 100. MTX was given at 10 mg/day on days þ 1, þ 3 and þ 6.
Acute GVHD was graded according to the consensus conference on aGVHD grading.
14 Among the 138 patients, 44 did not develop aGVHD, whereas 34, 45, 3 and 12 developed grades I, II, III and IV aGVHD, respectively. A total of 45 patients (32.6%) presented with cGVHD. In all, 58 patients died after transplantation (among these, 25 patients died before 100 days post transplant) ( Table 1) .
DNA extraction
Genomic DNA was extracted from peripheral blood samples obtained from recipients and donors before transplantation using a salting out method with a commercial DNA extraction kit (Dynal Biotech, Brown Deer, WI, USA) following the manufacturer's recommendations. DNA was quantified by spectrophotometry.
Analysis of TNFA, TNFB and TNFRII polymorphisms
The TNFA-1031 (T4C), -863 (C4A), -857 (C4T), -238 (G4A), TNFB þ 252 (A4G) and TNFRII codon 196 (T4G) SNPs were determined by multiplex SNaPshot technology (according to the previously described methods [15] [16] [17] , using an ABI fluorescence-based assay allelic discrimination method (Applied Biosystems, Foster city, CA, USA). The primers for PCR amplification and SNaPshot extension reactions were both designed to be aligned with the NCBI sequence databases using Primer3 software. The extension primer was designed to anneal immediately adjacent to the nucleotide at the mutation site, on either the sense or anti-sense DNA strand (Table 2) .
PCR was carried out in a total volume of 10 mL containing 50 ng genomic DNA, 0.1 mM of each primer, 0.3 mM each of dATP, dCTP, dTTP and dGTP, 1 unit of HotStarTaq polymerase (Qiagen Inc., Chatsworth, CA, USA), 4 mL of 1 Â buffer and 3.0 mM MgCl 2 . The samples were put through between 30 to 40 cycles of denaturation at 94 1C, annealing at specific primer temperatures, elongation at 72 1C and a final extension at 72 1C. PCR product amplification was verified by running 5 mL of product on a 2% agarose gel. The remaining product was then processed as per the ABI SNaPshot protocol, using primers designed for fluorescence dideoxynucleotide termination. SNP analysis was carried out using an ABI3130 genetic analyzer. Genotypes were determined automatically using Genemapper4.0 software (Applied Biosystems). Genotyping was confirmed by sequencing in 10% of randomly selected samples, as a quality control measure.
Statistical analyses
Only patients surviving 430 days were included in the analysis of aGVHD. Univariate analyses of the distribution of TNFA, TNFB and TNFRII genotypes in patients with and without aGVHD and cGVHD were performed using Fisher's exact tests. The incidences of relapse and survival were estimated using the Kaplan-Meier method, and the generalized Wilcoxon test was used to analyze the differences. The Cox proportional hazard model was applied to multivariate analysis of the effects of these characteristics on HSCT outcome. Statistical analysis was performed using SPSS software version 16.0. All probability values were two sided. Po0.05 was considered statistically significant, and values of P between 0.05 and 0.1 were considered to be indicative of a trend.
Results
TNFA, TNFB and TNFRII allele frequencies
The frequencies of the TNFA, TNFB and TNFRII genotypes in recipients and donors were almost equal and were consistent with previously reported results for the Chinese population and with the NCBI SNP databases (Table 3) . No significant deviations from the HardyWeinberg expected frequencies of these genotypes were observed in either donors or recipients (data not shown). In our study, the frequency of the TNFA mutation at position -238 (G-A) was very low (0.2%); the G/A genotype was not detected in any recipients and in only one donor, and no A/A homozygote donors or recipients were found. We therefore excluded the TNFA-238 polymorphism from subsequent analyses of HSCT outcome.
Cytokine gene polymorphisms and aGVHD and cGVHD Table 4 shows the results of univariate analysis of the association between cytokine genotypes and aGVHD. Recipients with TNFA-857C/C genotype or those receiving transplants from TNFA-857C/C donors developed aGVHD more frequently than those with the T allele (donor side: P ¼ 0.001; recipient side: P ¼ 0.039). P ¼ 0.028; recipient side: P ¼ 0.086). Donors and/or recipients with TNFA-857C/C genotype and recipients with TNFB þ 252 G allele-positive were also associated with higher incidences of grades II-IV aGVHD (Po0.05). HLA allele mismatching is the main cause of aGVHD development. To distinguish between the effects of HLA mismatching and those of cytokine gene polymorphisms, high-resolution HLA-A, -B, -C, -DRB1 and -DQB1 allelematched cases were analyzed (Table 4 ). Donor and/or recipient TNFA-857 and TNFB þ 252 genotypes also affected aGVHD incidence. The influence of TNFRII genotype on aGVHD was not significant, except for a tendency towards an association between recipient TNFRII genotype and aGVHD (P ¼ 0.074). These results suggest that the TNFA-857 and TNFB þ 252 genotypes affect the risk of aGVHD, independent of HLA mismatching. Neither recipient nor donor TNFA-1031 or TNFA-863 polymorphisms were associated with the risk of aGVHD in either the total cohort or in the HLA-matched cohort.
However, all the TNFA, TNFB and TNFRII alleles showed similar frequencies in patients with and without cGVHD (data not shown), indicating no association between cytokine gene polymorphisms in either recipients or donors and cGVHD. The results are given in Table 5 . Three variables were significantly associated with the risk of developing aGVHD: myeloablative conditioning (relative risk (RR) ¼ 3.771, P ¼ 0.004), donor with TNFA-857C/C genotype (RR ¼ 2.29, P ¼ 0.006) and TNFB þ 252 G allelepositive recipient (RR ¼ 1.789, P ¼ 0.036). Donor-recipient gender (donor female and recipient male) was found to be a less significant factor influencing the risk of aGVHD (RR ¼ 1.388, P ¼ 0.079). Myeloablative conditioning (RR ¼ 3.929, P ¼ 0.022), HLA mismatching (RR ¼ 1.691, P ¼ 0.048) and TNFA-857 C/C genotype donor (RR ¼ 3.748, P ¼ 0.002) were found to be significant risk factors associated with grades II-IV aGVHD. Being a TNFB þ 252 G allele-positive recipient was found to be a less significant risk factor for grades II-IV aGVHD (RR ¼ 1.823, P ¼ 0.063).
Distribution of TNFA, TNFB and TNFRII genotype in relation to relapse and survival Relapse was observed more frequently among patients who had not previously developed aGVHD (P ¼ 0.03; Figure 1 ). When the association of cytokine gene polymorphisms with relapse was examined, the relapse rate among recipients with TNFRII 196 T/T genotype was lower than that among recipients with other genotypes (P ¼ 0.05; Figure 2 ), but donor TNFRII 196 genotype had no significant influence on relapse rate. There was no association between relapse Table 5 Multivariate analysis of risk factors of aGVHD and grades II-IV aGVHD rate and TNFA or TNFB gene polymorphisms of recipient or donor.
On Kaplan-Meier analysis, no significant associations were found between donor or recipient TNFA, TNFB and TNFRII 196 genotype and either overall or relapse-free survival after transplantation. For this reason, multivariate analysis to investigate the impact of cytokine gene polymorphisms on survival was not undertaken.
Discussion
The results of multivariate analysis in this study demonstrated that HLA mismatching was a risk factor for aGVHD. However, despite HLA identity between patient and donor, B40% of patients receiving HLA-identical grafts still develop aGVHD due to differences in genes other than the HLA loci, or in minor histocompatibility antigens. 18 The results of recent studies that examined the roles of a wide range of cytokine gene polymorphisms in transplantation outcome, suggested that the initiation of aGVHD was influenced by some cytokine gene polymorphisms. [19] [20] [21] [22] TNFA alleles were the first non-HLA variants reported to be associated with GVHD in sibling myeloablative allo-HCT. 23 In this study, the effects of polymorphisms at positions -1031 (T4C), -863 (C4A), -857 (C4T) and -238 (G4A) on the outcome of unrelated HSCT were studied. Our results demonstrated that allo-HSCT involving TNFA-857 C/C-positive recipients and/or donors resulted in a higher incidence of aGVHD and grades II-IV aGVHD, which was independent of HLA mismatching. Although the exact influence of these polymorphisms on TNF-a function and expression is not fully understood, the localization of this polymorphism in the regulatory region suggests that it may contribute to regulation of the TNFA promoter. A Japanese HLA-matched unrelated bone marrow transplantation study described an association between the -1031T/-863C/-857C haplotype and a high incidence of severe aGVHD. 24 However, our study found no significant associations between -1031 and -863 polymorphisms and the risk of aGVHD. This discrepancy could be because 73% of the Japanese bone marrow transplantation cohort were subjected to total body irradiationconditioning regimens, which may cause the release of more inflammatory cytokines, such as TNF-a and IL-6, compared with regimens excluding radiation. This could result in increased endothelial cell damage that may precipitate the cytokine storm associated with aGVHD. 25, 26 In our study cohort, prophylaxis of GVHD consisted of CsA, short-term MTX and mycophenolate mofetil, and both MTX and mycophenolate mofetil can downregulate the production of TNF-a, which may thus reduce the influence of TNF-a on aGVHD. 27, 28 Two previous studies failed to find an association between the TNFB þ 252 polymorphism and aGVHD. 29, 30 The results of this study provide the first evidence that TNFB þ 252 G allele-positivity of recipients and/or donors was associated with an increased susceptibility to aGVHD in a Chinese population. The role of TNF-b in aGVHD is much less well known than that of TNF-a. Several recent studies have demonstrated an association between the TNFB þ 252 G allele and a higher risk of breast cancer and sarcoidosis, demonstrating a pivotal role for TNF-b in host cellular immunity. [31] [32] [33] Moreover, both TNFA and TNFB gene polymorphisms have been shown to be associated with TNF-a generation potential. Thus, TNFA and TNFB gene polymorphisms may have functional significance in diseases whose pathogenetic mechanisms include TNF-a production. 34, 35 TNFRII promotes T-cell proliferation and MHC class II-stimulated alloresponses. 36 TNF-TNFRII interactions are critical for the development of aGVHD in animal models and recombinant human soluble TNFRII fusion protein is currently used to treat steroid refractory GVHD. 37, 38 Our study indicates that transplants involving recipients and/or donors with TNFRII 196 T/T genotype had a higher risk of aGVHD, though the influence was not TNFA, TNFB and TNFRII gene polymorphisms and allo-HSCT H Xiao et al significant in an HLA-matched cohort and using multivariate analysis. Further studies are needed to determine whether this phenomenon is due to the direct influence of the SNP and/or to the combined influence of other gene polymorphisms or clinical risk factors.
Only recipient TNFRII polymorphism was related to relapse rate, and no significant associations were found between donor or recipient TNFA, TNFB or TNFRII 196 genotype and cGVHD, relapse or overall survival after transplantation. This could be because of differences in pathophysiology between aGVHD and cGVHD and stronger immunosuppressive therapy in patients with aGVHD.
Non-HLA immunogenetic analyses in HSCT may provide useful information on clinical markers that will aid patient counseling, donor selection, tailoring of immunosuppressive therapy and identification of novel therapeutic targets. 39 Further studies need to be conducted in defined, large HSCT cohorts, which should ideally be homogenous for disease, conditioning regimen and GVHD prophylaxis.
